retatrutide peptide vial Triple Agonist (GLP-1/GIP/GCG) GLP-3 Retatrutide (24mg vials) -

(2025) 'Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial' [Accessed 19 Jan

The older drugs have been successfully tested as a way to maintain weight after bariatric surgery, but they havent been studied among people coming off of GLP-1s, David Cummings, a professor at the University of Washington, told me

They are rarely tested in large human studies, and small short-term studies do not provide strong evidence 16

Peptides Skin does not advocate or encourage ingestion, injection, or use on humans or animals

e , Glucose tolerance test

The initial doses are designed purely to get your body used to the medicine and minimise side effects